NASDAQ:CVAC - Nasdaq - NL0015436031 - Common Stock - Currency: USD
3.3
+0.02 (+0.61%)
The current stock price of CVAC is 3.3 USD. In the past month the price decreased by -16.67%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 19.97 | 357.10B | ||
AMGN | AMGEN INC | 15.29 | 162.72B | ||
GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
NTRA | NATERA INC | N/A | 21.43B | ||
BIIB | BIOGEN INC | 8.54 | 20.49B | ||
SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
CureVac BV is a clinical-stage biopharmaceutical company, which engages in developing transformative medicines based on messenger ribonucleic acid (mRNA). The company is headquartered in Tuebingen, Baden-Wuerttemberg and currently employs 999 full-time employees. The company went IPO on 2020-08-14. Fueled by proprietary RNA technology platform combined with two decades of science and manufacturing, The Company is dedicated to creating novel treatments that enable the body to make its own prophylactic and therapeutic drugs.
CUREVAC NV
Friedrich-Miescher-Str. 15
Tuebingen BADEN-WUERTTEMBERG 72076 DE
CEO: Franz-Werner Haas
Employees: 1086
Company Website: https://www.curevac.com/
Investor Relations: https://www.curevac.com/en/investor-relations/
Phone: 49707198830
The current stock price of CVAC is 3.3 USD. The price increased by 0.61% in the last trading session.
The exchange symbol of CUREVAC NV is CVAC and it is listed on the Nasdaq exchange.
CVAC stock is listed on the Nasdaq exchange.
14 analysts have analysed CVAC and the average price target is 7.87 USD. This implies a price increase of 138.44% is expected in the next year compared to the current price of 3.3. Check the CUREVAC NV stock analysts ratings, price target forecast and up-and down grades for more detailed information.
CUREVAC NV (CVAC) has a market capitalization of 740.32M USD. This makes CVAC a Small Cap stock.
CUREVAC NV (CVAC) currently has 1086 employees.
CUREVAC NV (CVAC) has a support level at 3.29 and a resistance level at 3.59. Check the full technical report for a detailed analysis of CVAC support and resistance levels.
The Revenue of CUREVAC NV (CVAC) is expected to grow by 700.96% in the next year. Check the estimates tab for more information on the CVAC EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
CVAC does not pay a dividend.
CUREVAC NV (CVAC) will report earnings on 2025-04-22, after the market close.
The PE ratio for CUREVAC NV (CVAC) is 6.6. This is based on the reported non-GAAP earnings per share of 0.5 and the current share price of 3.3 USD. Check the full fundamental report for a full analysis of the valuation metrics for CVAC.
The outstanding short interest for CUREVAC NV (CVAC) is 2.96% of its float. Check the ownership tab for more information on the CVAC short interest.
ChartMill assigns a technical rating of 3 / 10 to CVAC. When comparing the yearly performance of all stocks, CVAC is one of the better performing stocks in the market, outperforming 79.05% of all stocks.
ChartMill assigns a fundamental rating of 6 / 10 to CVAC. CVAC is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average.
Over the last trailing twelve months CVAC reported a non-GAAP Earnings per Share(EPS) of 0.5. The EPS increased by 134.53% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | 19.93% | ||
ROA | 12.68% | ||
ROE | 14.94% | ||
Debt/Equity | 0.05 |
ChartMill assigns a Buy % Consensus number of 79% to CVAC. The Buy consensus is the average rating of analysts ratings from 14 analysts.
For the next year, analysts expect an EPS growth of 164.54% and a revenue growth 700.96% for CVAC